Interviewing the CEO who uses Probiotics as Needle-free Vaccines

This is my first interview from BioTrinity 2016 in London. I met with Tom Johnston, CEO of Mucosis, to learn more about the needle-free vaccine platform he is developing.

logo_mucosis

Mucosis is a biotechnology company based in Gröningen, Netherlands (a city we covered here for its medtech innovation). It was founded in 2007 and has raised over €20M so far.

The company is using safe probiotics as antigen presenters to develop an innovative mucosal vaccines which can be administered needle-free via the nose or mouth.

The lead product is preparing for a Phase I trial in September, with hopes to potentially start Phase II next year. Notably, the company got a €3.7M funding from the Wellcome Trust earlier this year, which is a great recognition of the potential of the platform.


So I asked Tom my more pressing questions to better understand their technology…


Feature Image Credit: Philip Hemme interviewing Tom Johnston at BioTrinity 2016

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.